TITLE

Expert panel discusses bleeding associated with medications for ACS

PUB. DATE
February 2010
SOURCE
Cardiology Today;Feb2010, Vol. 13 Issue 2, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article highlights a round table discussion held by cardiologists during the American Heart Association's Scientific Sessions in November 2009 in Orlando, Florida, in which they discussed bleeding associated with medications for acute coronary syndromes.
ACCESSION #
47733196

 

Related Articles

  • Cappella Medical Receives Regulatory Approval in India to Market its Proprietary Sideguard(r) Technology Platform.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article offers information on the approval received by Cappella Medical Devices Ltd. to market its flagship Sideguard coronary stent system in India. It reports that the company's proprietary stent design provides cardiologist a novel solution to preserve the side branch and reduce the...

  • Pharmacoeconomics of Anticoagulants in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Huston, S. A.; Hawkins, D. // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1197 

    Economic evaluation plays an important role during almost all stages of pharmaceutical design and use. This paper reviews the recent pharmacoeconomic literature on the use of anticoagulants for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). Both ACS and PCI are...

  • Treatment Approaches.  // Current Medical Literature: Cardiology;2006, Vol. 25 Issue 3, p69 

    The article presents several studies related to treatment approaches in heart diseases. One study concluded that fondaparinux, a synthetic pentasaccharide, is as efficient as enoxaparin for the treatment of acute coronary syndrome patients. Another study showed that risk of death or myocardial...

  • DES debate drives demand for better data, standards.  // Medical Technology & Devices Week;9/8/2008, Vol. 6 Issue 36, p4 

    This article reports that the controversy over the use of drug-eluting stents (DES) for treating coronary disease could be heard throughout the sessions, seminars and press conferences at the 2008 annual congress of the European Society of Cardiology. Without clear practice guidelines,...

  • Weighing Benefits and Risks � The FDA's Review of Prasugrel. Unger, Ellis F. // New England Journal of Medicine;9/3/2009, Vol. 361 Issue 10, p942 

    The author discusses the benefits and risks of using prasugrel, which was approved by the U.S. Food and Drug Administration (FDA) for reducing thrombotic cardiovascular events in patients suffering from myocardial infarction or unstable angina. He says that prasugrel reduced end-point events,...

  • APPRAISE-I: Apixaban reduced ischemic events, increased bleeding risk. Raible, Eric // Cardiology Today;Nov2008, Vol. 11 Issue 11, p26 

    The article reports that the APPRAISE-I study indicates that apixaban reduces ischemic events but increases risk for bleeding in patients with recent acute coronary syndromes (ACS). Dr. John H. Alexander of the Duke University Health Center states that though novel anticoagulants offer an...

  • FDA Actions: New Oral Antiplatelet Agent.  // Travel Medicine Advisor;Sep2009 Supplement, p1 

    The article announces the approval by the U.S. Food and Drug Aministration (FDA) of the use of prasugrel, a new oral anti platelet agent indicated for patients with acute coronary syndrome who are to be managed by angioplasty. The approval was based on a head-to-head study with clopidogrel that...

  • An excess dose of enoxaparin increased risk for death in the non--ST-segment elevation acute coronary syndrome.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p22 

    The article presents a study that investigates the relationship between the enoxaparin dose and risk for in-hospital major bleeding and death of patients with the non-ST-segment elevation acute coronary syndrome (ACS). Cohort analysis has been conducted on the 10,678 patients in the 332...

  • Should acetylsalicylic acid (ASA) therapy for prevention of thromboembolic events be stopped prior to surgical extractions? Dodson, Tom // Evidence-Based Dentistry;Sep2012, Vol. 13 Issue 3, p89 

    The author discusses aspects of a randomised controlled trial which explores the association of acetylsalicylic acid (ASA) therapy with the degree of bleeding that occur during tooth extraction in patients with coronary artery disease (CAD). He notes the use of a double blind randomised...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics